CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple...
Phase 1
Bethesda, Maryland, United States and 2 other locations
lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).FDA has approved selinexor plus dexamethaso ...
Phase 2
Columbia, Maryland, United States and 9 other locations
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients...
Phase 2
Columbia, Maryland, United States and 11 other locations
CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15...
Phase 1
Bethesda, Maryland, United States
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...
Phase 1
Bethesda, Maryland, United States and 12 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Columbia, Maryland, United States and 145 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
Baltimore, Maryland, United States and 9 other locations
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Baltimore, Maryland, United States and 31 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Baltimore, Maryland, United States and 59 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Baltimore, Maryland, United States and 211 other locations
Clinical trials
Research sites
Resources
Legal